Cargando...
CADD-57. THE EFFICACY OF THERAPY WITH ABT-414, AN EGFR-TARGETING ADC, IS POTENTIALLY ALTERED BY HETEROZYGOUS DELETION OF THE ENDOCYTIC TRAFFICKING REGULATOR RBSN
Therapy with ABT-414 (depatux-m), a humanized monoclonal antibody drug conjugate (ADC) directed toward EGFRvIII and activated wild-type EGFR linked to MMAF, has demonstrated promising clinical activity in glioblastoma (GBM) patients with amplified EGFR and is currently being evaluated in clinical tr...
Gardado en:
| Publicado en: | Neuro Oncol |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Oxford University Press
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6216917/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.1182 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|